KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 90 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,095,554 | +19.3% | 944,502 | +11.5% | 0.00% | 0.0% |
| Q2 2023 | $7,624,854 | +651.4% | 847,206 | +556.3% | 0.00% | – |
| Q1 2023 | $1,014,687 | +25.7% | 129,095 | +8.1% | 0.00% | – |
| Q4 2022 | $807,327 | -84.0% | 119,427 | -65.6% | 0.00% | -100.0% |
| Q3 2022 | $5,032,000 | -6.8% | 346,822 | -36.8% | 0.00% | 0.0% |
| Q2 2022 | $5,402,000 | +172.6% | 548,981 | +308.3% | 0.00% | – |
| Q1 2022 | $1,982,000 | +761.7% | 134,470 | +672.5% | 0.00% | – |
| Q4 2021 | $230,000 | -80.8% | 17,406 | -74.6% | 0.00% | – |
| Q3 2021 | $1,197,000 | -65.5% | 68,562 | -52.6% | 0.00% | – |
| Q2 2021 | $3,468,000 | -42.1% | 144,748 | -37.9% | 0.00% | -100.0% |
| Q1 2021 | $5,991,000 | +27.1% | 233,211 | -6.1% | 0.00% | 0.0% |
| Q4 2020 | $4,715,000 | +559.4% | 248,300 | +165.6% | 0.00% | – |
| Q1 2020 | $715,000 | +505.9% | 93,503 | +817.2% | 0.00% | – |
| Q3 2019 | $118,000 | -74.7% | 10,194 | -51.6% | 0.00% | – |
| Q2 2019 | $467,000 | – | 21,072 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |